Immune microenvironmental shift along human colorectal adenoma-carcinoma sequence: Is it relevant to tumor development, biomarkers and biotherapeutic targets?

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 4, 2012, Pages 367-377

  Cui, Guanglin ^a,b,c   Shi, Yingpeng ^a   Cui, Jing ^a   Tang, Fuai ^a   Florholmen, Jon ^b,c  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

adenoma; carcinogenesis; colorectum; immunosuppressive; immunosurveillance

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CANCER VACCINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DENDRITIC CELL VACCINE; EVEROLIMUS; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

CANCER IMMUNOTHERAPY; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MEDICAL LITERATURE; NONHUMAN; PATHOGENESIS; PRECANCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ADENOMA; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84858643422     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.648950     Document Type: Review

References (132)

1. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002;89:845-60. (Pubitemid 34779568)
2. Nakamori M, Iwahashi M, Nakamura M, Ueda K, Zhang X, Yamaue H. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer. Clin Cancer Res 2003;9:2357-65. (Pubitemid 36687663)
3. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 2010;31:31-8.
4. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-29.
5. Yang SY, Sales KM, Fuller B, Seifalian AM, Winslet MC. Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 2009;15:225-33.
6. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010;29:3033-43.
7. Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Molecular biology of colorectal cancer. Curr Probl Cancer 1997;21:233-300.
8. Nihon-Yanagi Y, Terai K, Murano T, Matsumoto T, Okazumi S. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer immunol immunother 2011.
9. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med 2010;8:112.
10. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer immunol immunother 2011;60:319-26.
11. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007;67:1883-6. (Pubitemid 46424201)
12. Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006;130:103-24.
13. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37. (Pubitemid 43053650)
14. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48. (Pubitemid 39094044)
15. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007;56:1687-700. (Pubitemid 47313090)
16. Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006;24:1163-77. (Pubitemid 44427504)
17. Shunyakov L, Ryan CK, Sahasrabudhe DM, Khorana AA. The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer 2004;4:38-45. (Pubitemid 38811510)
18. Karlsson M, Lindberg K, Karlen P, Ost A, Thorn M, Winqvist O, et al. Evidence for immunosurveillance in intestinal premalignant lesions. Scand J Immunol 2010; 71:362-8.
19. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
20. Banner BF, Sonmez-Alpan E, Yousem SA. An immunophenotypic study of the inflammatory cell populations in colon adenomas and carcinomas. Mod Pathol 1993;6:295-301.
21. Cui G, Yuan A, Vonen B, Florholmen J. Progressive cellular response in the lamina propria of the colorectal adenoma-carcinoma sequence. Histopathology 2009;54:550-60.
22. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 2003;10:309-13.
23. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007;13:1472-9. (Pubitemid 46450437)
24. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007;5:62.
25. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 2010;11:19.
26. Bateman WJ, Donnellan I, Fraser IA, Wong LS, Morris AG. Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma. Cancer Immunol Immunother 1995;41:61-7.
27. Toomey D, Harmey J, CondronC,Kay E, Bouchier-Hayes D. Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 1999;28:29-41. (Pubitemid 29072821)
28. Jedinak A, Dudhgaonkar S, Sliva D. Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 2007;215:242-9.
29. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645-54. (Pubitemid 41607555)
30. Luebbers EL, Pretlow TP, Emancipator SN, Boohaker EA, Pitts AM,Macfadyen AJ, et al. Heterogeneity and prognostic significance of macrophages in human colonic carcinomas. Cancer Res 1985;45:5196-200. (Pubitemid 16236214)
31. Pisano C, Ottaiano A, Tatangelo F, Di Bonito M, Falanga M, Iaffaioli VR, et al. Cyclooxygenase-2 expression is associated with increased size in human sporadic colorectal adenomas. Anticancer Res 2005;25:2065-8. (Pubitemid 40904605)
32. Yang W, Arii S, Gorrin-Rivas MJ, Mori A, Onodera H, Imamura M. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 2001;91:1277-83. (Pubitemid 32267038)
33. Rose-John S,Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 2007;11:613-24. (Pubitemid 46730080)
34. Bamba H, Ota S, Kato A, Adachi A, Itoyama S, Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999;83:470-5. (Pubitemid 29489860)
35. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.
36. Schwaab T, Weiss JE, Schned AR, Barth RJ Jr. Dendritic cell infiltration in colon cancer. J Immunother 2001;24:130-7. (Pubitemid 32183059)
37. Yamaguchi N, Hiraoka S, Mukai T, Takeuchi N, Zhou XY, Ono S, et al. Induction of tumor regression by administration of B7-Ig fusion proteins: mediation by type 2 CD8+ T cells and dependence on IL-4 production. J Immunol 2004;172:1347-54. (Pubitemid 38116775)
38. Yuan A, Steigen SE, Goll R, Vonen B, Husbekk A, Cui G, et al. Dendritic cell infiltration pattern along the colorectal adenoma-carcinoma sequence. APMIS 2008;116:445-56.
39. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4. (Pubitemid 28376536)
40. Banner BF, Savas L, Baker S, Woda BA. Characterization of the inflammatory cell populations in normal colon and colonic carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;64:213-20. (Pubitemid 23309418)
41. Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007;7:7.
42. Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 2006;1:e129.
43. Gallimore A, Godkin A. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 2008;123:157-63.
44. Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004;91:469-75. (Pubitemid 38491119)
45. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 2006;86:231-45. (Pubitemid 43276955)
46. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes- Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010;29:1093-102.
47. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder- Stapel A, Hermans J, van de Velde CJ, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immuno-histochemical study. BMC Cancer 2001;1:7.
48. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, et al. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 2005;23:953-64. (Pubitemid 46202315)
49. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-22. (Pubitemid 44922352)
50. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006;6:476-83.
51. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 1989;63:496-503. (Pubitemid 19038466)
52. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005;11:2576-82. (Pubitemid 40569456)
53. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-12. (Pubitemid 43165918)
54. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68.
55. Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000;46:S52-61.
56. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996;42:1-8.
57. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8. (Pubitemid 38082155)
58. Barth RJ Jr, Camp BJ, Martuscello TA, Dain BJ, Memoli VA. The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer 1996;78:1168-78. (Pubitemid 26303881)
59. Cui G,Goll R,Olsen T,Steigen SE,Husebekk A,Vonen B, etal. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother 2007;56:985-95. (Pubitemid 46675303)
60. Berghella AM, Contasta I, Pellegrini P, Del Beato T, Adorno D. Are immunological mechanisms involved in colon cancer and are they possible markers for biotherapy improvement? Cancer Biother Radiopharm 2006;21:468-87. (Pubitemid 44747605)
61. Contasta I, Pellegrini P, Berghella AM, Del Beato T, Adorno D. Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy. Cancer Biother Radiopharm 2006;21:488-505. (Pubitemid 44753103)
62. Pellegrini P, Berghella AM, Contasta I, Del Beato T, Adorno D. The study of a patient's immune system may prove to be a useful noninvasive tool for stage classification in colon cancer. Cancer Biother Radiopharm 2006;21:443-67.
63. Piancatelli D, Romano P, Sebastiani P, Adorno D, Casciani CU. Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother 1999;22:25-32. (Pubitemid 29042287)
64. Berghella AM, Pellegrini P, Del Beato T, Marini M, Tomei E, Adorno D, et al. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother 1998;45:241-9. (Pubitemid 128759558)
65. Chung YC, Chang YF. Significance of inflammatory cytokines in the progressionof colorectal cancer.Hepatogastroenterology 2003;50:1910-13.
66. ContastaI,BerghellaAM,PellegriniP,AdornoD.Passagefrom normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions. Cancer Biother Radiopharm 2003;18:549-57. (Pubitemid 37082374)
67. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002;102:169-78. (Pubitemid 34171516)
68. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer 2000;82:1009-12. (Pubitemid 30128851)
69. O'Hara RJ, Greenman J, Drew PJ, McDonald AW, Duthie GS, Lee PW, et al. Impaired interleukin-12 production is associated with a defective anti-tumor response in colorectal cancer. Dis Colon Rectum 1998;41:460-3. (Pubitemid 28169671)
70. O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998;4:1943-8. (Pubitemid 28369179)
71. Shibata M, Nezu T, Kanou H, Abe H, Takekawa M, Fukuzawa M. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol 2002;34:416-20. (Pubitemid 34258317)
72. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, et al. Interferon-gamma and cancer immunoediting. Immunol Res 2005;32:231-45.
73. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, et al. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer 1999;84:326-30. (Pubitemid 29256763)
74. Osawa E, Nakajima A, Fujisawa T, Kawamura YI, Toyama- Sorimachi N, Nakagama H, et al. Predominant T helper type 2-inflammatory responses promotemurine colon cancers. Int J Cancer 2005;118:2232-6.
75. Baier PK, Wolff-Vorbeck G, Eggstein S, Baumgartner U, Hopt UT. Cytokine expression in colon carcinoma. Anticancer Res 2005;25:2135-9. (Pubitemid 40908891)
76. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 2005;11:1210-14. (Pubitemid 40353010)
77. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47. (Pubitemid 36818244)
78. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7. (Pubitemid 39551661)
79. Schottelius AJ, Dinter H. Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer. Cancer Treat Res 2006;130:67-87.
80. Ngan CY, Yamamoto H, Seshimo I, Tsujino T, Man IM, Ikeda JI, et al. Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br J Cancer 2007.
81. Wendum D, Masliah J, Trugnan G, Flejou JF. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 2004;445:327-33. (Pubitemid 39517756)
82. DuBois RN, Smalley WE. Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol 1996;31:898-906. (Pubitemid 27042276)
83. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9. (Pubitemid 27203783)
84. Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996;111:1134-40. (Pubitemid 26327618)
85. Ota S, Bamba H, Kato A, Kawamoto C, Yoshida Y, Fujiwara K. Review article: COX-2, prostanoids and colon cancer. Aliment Pharmacol Ther 2002;16:102-6. (Pubitemid 41771468)
86. Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF, Powell DW. Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 2004;10:5870-9. (Pubitemid 39180968)
87. Einspahr JG, Krouse RS, Yochim JM, Danenberg PV, Danenberg KD, Bhattacharyya AK, et al. Association between Cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res 2003;63:3891-3. (Pubitemid 36917900)
88. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I-anindependent prognostic factor. Tumour Biol 2005;26:186-94. (Pubitemid 41379744)
89. Cui G, Yuan A, Goll R, Olsen T, Husebekk A, Vonen B, et al. Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2007;56:1993-2001. (Pubitemid 47512619)
90. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9. (Pubitemid 26404280)
91. Daniel P, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska O, Malecka-Panas E. Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int J Colorectal Dis 2007;22:1165-72. (Pubitemid 47304784)
92. Gulubova M, Manolova I, Ananiev J, Julianov A, Yovchev Y, Peeva K. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer. Int J Colorectal Dis 2010;25:591-9.
93. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31:220-7.
94. Maeda H, Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996;156:73-8.
95. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68:3915-23.
96. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, HY. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
97. Kaklamanis L, Trichas M, Amarantidis K, Spathari N, Micheli A, Karayiannakis A, et al. VEGF expression in the colorectal adenoma-carcinoma sequence. Oncol Res 2006;15:445-51.
98. Staton CA, Chetwood AS, Cameron IC, Cross SS, Brown NJ, Reed MW. The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut 2007;56:1426-32. (Pubitemid 47517839)
99. Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 2010;10:203.
100. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998;93:249-52. (Pubitemid 29063978)
101. Werther K, Sorensen S, Christensen IJ, Nielsen HJ. Circulating vascular endothelial growth factor six months after primary surgery as a prognostic marker in patients with colorectal cancer. Acta Oncol 2003;42:837-45. (Pubitemid 38091184)
102. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003;200:183-94. (Pubitemid 36748027)
103. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-53.
104. Wu X, Li D, Liu Z, Wan X, Wu Y, Jiang C, et al. Vascular endothelial growth factor 1498C/T, 936C/T polymorphisms associated with increased risk of colorectal adenoma: a Chinese case-control study. Mol Biol Rep 2011;38:1949-55.
105. Tilstone C. Immunological markers to replace TNM staging? Lancet Oncol 2006;7:890.
106. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4. (Pubitemid 44498003)
107. Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, et al. Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. Curr Top Microbiol Immunol 2010.
108. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010;222:350-66.
109. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2011.
110. Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009;20:15-26.
111. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-18. (Pubitemid 41437845)
112. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008;68:323-8. (Pubitemid 351380135)
113. Matsuda A, Furukawa K, Suzuki H, Kan H, Tsuruta H, Matsumoto S, et al. Does impaired TH1/TH2 balance cause postoperative infectious complications in colorectal cancer surgery? J Surg Res 2007;139:15-21. (Pubitemid 46482576)
114. Matsuda A, Furukawa K, Takasaki H, Suzuki H, Kan H, Tsuruta H, et al. Preoperative oral immune-enhancing nutritional supplementation corrects TH1/TH2 imbalance in patients undergoing elective surgery for colorectal cancer. Dis Colon Rectum 2006;49:507-16.
115. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol 2010;22:251-7.
116. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-65. (Pubitemid 46697909)
117. He XZ, Wang L, Zhang YY. An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells. World J Gastroenterol 2008;14:532-40. (Pubitemid 351320818)
118. Lesterhuis WJ, de Vries IJ, Aarntzen EA, de Boer A, Scharenborg NM, van de Rakt M, et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer 2010;103:1415-21.
119. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, et al. Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res 2009;2:310-21. [120] Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. (Pubitemid 44315980)
120. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80. (Pubitemid 40365348)
121. Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology 2010;138:969-80;e961-963.
122. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci USA 2008;105:13544-9.
123. Fujishita T, Aoki M, Taketo MM. The role of mTORC1 pathway in intestinal tumorigenesis. Cell Cycle 2009;8:3684-7.
124. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clinical Cancer Res 1999;5:2963-70. (Pubitemid 29493976)
125. Cilley JC, Barfi K, Benson AB 3rd, Mulcahy MF. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2007;7:739-49. (Pubitemid 46707194)
126. Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9.
127. Mulcahy MF, Benson AB 3rd. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2005;5:997-1005. (Pubitemid 41032854)
128. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol 2006;63:321-9.
129. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005;4:217-20. (Pubitemid 41365319)
130. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005;28:187-96.
131. Rose-John S, Schooltink H. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res 2007;174:57-66.
132. Cui G, Yuan A, Goll R, Vonen B, Florholmen J. Dynamic changes of interleukin-8 network along the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother 2009;58:1897-905.